# Biosimulation * **Definition:** A technology that uses computer simulations to model biological processes and systems for drug discovery and development. * **Taxonomy:** Healthcare Topics / Biosimulation ## News * Selected news on the topic of **Biosimulation**, for healthcare technology leaders * 768 news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/19/2025 | [**Medical Telemetry System Market Expansion 2025: Top Emerging Regions to Watch**](https://www.linkedin.com/pulse/medical-telemetry-system-market-expansion-2025-top-emerging-0nmse/) | [[Linkedin]] | | 5/16/2025 | [**Health & Wellness Devices Market Forecast to Surpass Revenues of $900 Billion by 2030**](https://finance.yahoo.com/news/health-wellness-devices-market-forecast-132000785.html) | [[Yahoo Finance]] | | 5/12/2025 | [**Healthcare Staffing Archives - HealthTech Magazines**](https://www.healthtechmagazines.com/category/healthcare-staffing/) | [[Health Tech Magazines]] | | 5/8/2025 | [**HealthSnap Named "Best Clinical Efficiency Solution" in 9th Annual MedTech Breakthrough ...**](https://www.prnewswire.com/news-releases/healthsnap-named-best-clinical-efficiency-solution-in-9th-annual-medtech-breakthrough-awards-program-302450199.html) | [[PR Newswire]] | | 4/25/2025 | [**Patient-Centric Care: Advancements in Digital Health Tools**](https://www.cioreview.com/news/patientcentric-care-advancements-in-digital-health-tools-nid-40926-cid-281.html) | [[CIO Review]] | | 4/25/2025 | [**Global Virtual Care Market to Surge: From $7.9 Billion in 2023 to $24.1 Billion by 2030 at a ...**](https://www.prnewswire.com/news-releases/global-virtual-care-market-to-surge-from-7-9-billion-in-2023-to-24-1-billion-by-2030-at-a-19-cagr---valuates-reports-302438427.html) | [[PR Newswire]] | | 4/22/2025 | [**The Top 25 Healthcare AI Companies of 2025**](https://thehealthcaretechnologyreport.com/the-top-25-healthcare-ai-companies-of-2025/) | [[Healthcare Technology Report]] | | 4/22/2025 | [**Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network**](https://finance.yahoo.com/news/zacks-industry-outlook-highlights-veeva-123900941.html) | [[Yahoo Finance]] | | 4/22/2025 | [**The Growing Influence of Digital Health in Pharma - LinkedIn**](https://www.linkedin.com/pulse/growing-influence-digital-health-pharma-milan-sojitra-wgdwe) | [[Linkedin]] | | 3/4/2025 | [**AI, MedTech And Big Tech: Who Will Lead The Next Medical Revolution? - Forbes**](https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/2025/03/04/ai-medtech-and-big-tech-who-will-lead-the-next-medical-revolution/) | [[Forbes]] | | 3/4/2025 | [**Portable Medical Devices Market to Reach USD 191.1 Billion by 2035, Driven by AI ...**](https://finance.yahoo.com/news/portable-medical-devices-market-reach-123000217.html) | [[Yahoo Finance]] | | 3/4/2025 | [**Global Healthcare Mobility Solutions Market to Exhibit Tremendous Growth at a CAGR of**](https://finance.yahoo.com/news/global-healthcare-mobility-solutions-market-180000404.html) | [[Yahoo Finance]] | | 2/24/2025 | [**Jelvix Named Among the Top 100 Healthcare Tech Companies**](https://www.healthcaredive.com/press-release/20250221-jelvix-named-among-the-top-100-healthcare-tech-companies/) | [[Healthcare Dive]] | | 2/22/2025 | [**Black Book Research Releases 2025 Rural Healthcare IT Solutions Report Addressing ...**](https://www.newswire.com/news/black-book-research-releases-2025-rural-healthcare-it-solutions-report-22524487) | [[Newswire]] | | 2/16/2025 | [**The Rise of Decentralized Clinical Trials: Transforming Medical Research in the Digital Age**](https://medium.com/@anand.butani/the-rise-of-decentralized-clinical-trials-transforming-medical-research-in-the-digital-age-14de2e771e75) | [[Medium]] | | 1/24/2025 | [**Zacks Industry Outlook Enovis, Omnicell and Phreesia - Nasdaq**](https://www.nasdaq.com/articles/zacks-industry-outlook-enovis-omnicell-and-phreesia) | [[Nasdaq]] | | 1/22/2025 | [**Exploring High Growth Tech Stocks in January 2025 - Yahoo Finance**](https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-180719232.html) | [[Yahoo Finance]] | | 1/13/2025 | [**Cellworks' Computational Biosimulation Lab Secures CLIA Certification to Advance Personalized Therapy Decision Support**](http://www.businesswire.com/news/home/20250113491724/en/Cellworks%E2%80%99-Computational-Biosimulation-Lab-Secures-CLIA-Certification-to-Advance-Personalized-Therapy-Decision-Support/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 1/13/2025 | [**Cellworks' Computational Biosimulation Lab Secures CLIA Certification to Advance ...**](https://finance.yahoo.com/news/cellworks-computational-biosimulation-lab-secures-140000582.html) | [[Yahoo Finance]] | | 12/21/2024 | [**Industry Revenue Insights and Market Worth with a Projected CAGR of 8.7or 2024 to 2031**](https://www.linkedin.com/pulse/exploring-medical-saas-system-market-industry-revenue-insights-zmsxf) | [[Linkedin]] | | 12/20/2024 | [**Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4AGR - MarketsandMarkets™**](https://www.prnewswire.com/news-releases/artificial-intelligence-in-oncology-market-to-hit-us-11-52-billion-by-2030-with-29-4-cagr--marketsandmarkets-302336930.html) | [[PR Newswire]] | | 12/12/2024 | [**Biosimulation Industry Forecast, 2029: Analysis of Case Studies, Market Dynamics ...**](https://finance.yahoo.com/news/biosimulation-industry-forecast-2029-analysis-100200057.html) | [[Yahoo Finance]] | | 11/22/2024 | [**Biosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7AGR - MarketsandMarkets™.**](https://www.globenewswire.com/news-release/2024/11/22/2985889/0/en/Biosimulation-Market-to-Hit-USD-9-18-Billion-by-2029-with-16-7-CAGR-MarketsandMarkets.html) | [[Globe Newswire]] | | 11/22/2024 | [**Biosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7AGR - Yahoo Finance**](https://finance.yahoo.com/news/biosimulation-market-hit-usd-9-123000776.html) | [[Yahoo Finance]] | | 10/30/2024 | [**Biosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7AGR - PR Newswire**](https://www.prnewswire.com/news-releases/biosimulation-market-to-hit-usd-9-18-billion-by-2029-with-16-7-cagr--marketsandmarkets-302289847.html) | [[PR Newswire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Simulations Plus, Inc.**: A leading provider of biosimulation software that enhances drug development processes through advanced modeling techniques. - **Simulations Plus**: Recognized for its advanced biosimulation solutions that integrate AI/ML and pharmacokinetic modeling to enhance drug discovery and development. - **GenBio AI**: A company that has launched the world's first AI-Driven Digital Organism (AIDO) to simulate and predict complex biological outcomes. - **Dassault Systèmes**: Key player in the biosimulation market, employing strategies like acquisitions and product innovations. - **Turbine**: A biological simulation company utilizing AI for predictive modeling of human cells. - **Scale Biosciences**: A company that has launched advanced technologies for single-cell genomics, promoting large-scale research initiatives. - **Certara, Inc.**: Offers AI-driven biosimulation software to accelerate drug development and improve the efficiency of clinical trials. - **Ichnos Sciences**: Collaborated with Certara to utilize advanced biosimulation techniques for predicting first-in-human dosing. - **Cellworks Group**: Utilizes biosimulation platforms to predict treatment outcomes and personalize cancer therapies, particularly in non-small cell lung cancer. - **Cellworks Group, Inc.**: A company that has developed a CLIA-certified biosimulation platform for personalized cancer therapy, utilizing mechanistic models to predict patient responses based on genomic data. - **Certara**: A leading provider of biosimulation software and services, focusing on drug development and regulatory compliance. - **Biosynth**: A global supplier of critical raw materials and services to the life sciences industry, enhancing diagnostics and pharmaceutical capabilities. - **Cellworks Group Inc.**: Focuses on computational biosimulation to model tumor behavior and evaluate personalized treatment strategies, particularly in cancer therapies. ### Partnerships and Collaborations - **Scale Biosciences with Ultima Genomics and NVIDIA**: Collaboration to provide resources and technology for the '100 Million Cell Challenge' in single-cell genomics. - **Simulations Plus and USC**: Collaborating on a project funded by the NIH to enhance ligand-based virtual screening for drug discovery by integrating water-ligand interactions. - **Simulations Plus and University of Connecticut**: Collaborating on a project funded by the FDA to develop and validate IVIVCs for long-acting injectable technologies. - **Stanford University**: A collaborative effort to develop the world's first virtual human cell using AI and extensive biological data. - **Simulations Plus and Enabling Technologies Consortium (ETC)**: Collaborating to enhance the GastroPlus platform for improved in vitro-in vivo correlation (IVIVC) in oral drug delivery. - **Certara and Vyasa Analytics**: Certara expanded its capabilities in biosimulation through the acquisition of Vyasa Analytics, positioning itself for long-term growth in the pharmaceutical sector. - **Simulations Plus and University of Strathclyde**: Working together with InnoGI Technologies on a project funded by the FDA to develop alternative methods for assessing the clinical performance of amorphous solid dispersion formulations. - **Simulations Plus, University of Strathclyde, and InnoGI Technologies**: Collaborating on a project to develop alternative methods for assessing clinical performance of amorphous solid dispersion formulations. - **Tempus and Takeda**: An expanded collaboration to enhance oncology research through data-driven approaches and biological modeling. - **Harvard University, MIT, and University of Edinburgh**: Collaborative research team developing a synthetic biology platform for efficient nanosensor detection. - **Certara and Ichnos Glenmark Innovation**: Collaborated to predict and select the first-in-human dose for ISB 2001, utilizing a virtual clinical trial platform to enhance patient safety and efficacy. - **Converge Bio and Compugen**: Partnered to support predictive discovery efforts in immuno-oncology. - **Aion Labs**: Launched startups ProPhet and CombinAble.AI to enhance drug discovery and therapeutic development through AI. - **HealthSnap**: Recognized for its integrated virtual care management platform, enhancing remote patient monitoring. - **Certara and FDA**: Collaboration to develop the Non-Animal Navigator™ solution, aiding biopharmaceutical companies in reducing animal testing. - **Certara and Chemaxon**: Certara has signed a definitive agreement to acquire Chemaxon, enhancing its model-informed drug development portfolio. - **Cincinnati Children's and Andor Health**: Expanded partnership to improve access to care using AI-driven solutions in healthcare settings. - **Commure and HealthTap**: Partnership to create a unified healthcare solution integrating EHR systems and AI tools for improved patient care. - **Ellipsis Health and Ceras Health**: Formed a partnership to improve mental health care through real-time severity scoring. ### Innovations, Trends, and Initiatives - **Biosimulation Technologies**: Incorporates computer-aided modeling and simulation techniques to forecast biological processes, significantly aiding drug discovery and precision medicine. - **Biosimulation Software**: Certara's software accelerates drug development processes, enhancing the efficiency of clinical trials. - **Biosimulation Market Growth**: Projected to grow from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, with a CAGR of 16.7%. - **Biosimulation Software Growth**: Certara reported a 26% increase in software revenue driven by strong performance in biosimulation offerings. - **Growth of Biosimulation Market**: The global biosimulation market is projected to grow from USD 4.24 billion in 2024 to USD 9.18 billion by 2029, driven by the need for better drug pharmacokinetics predictions. - **AI and Machine Learning Integration**: Biosimulation solutions are increasingly incorporating AI/ML, physiologically based pharmacokinetics, and quantitative systems pharmacology. - **CLIA-Certified Biosimulation Platform**: Cellworks' platform for personalized cancer therapy that predicts patient-specific responses to therapies based on genomic data. - **Biostimulation SDK**: DeepWell's SDK aims to integrate into immersive media to enhance treatments for stress and hypertension. - **AI-Driven Digital Organism (AIDO)**: GenBio AI's initiative to create models that simulate biological outcomes, representing a paradigm shift in understanding living systems. - **Digital Twins in Healthcare**: Emerging as a transformative tool for drug discovery and precision medicine, enabling real-time simulations of biological systems. - **Digital Twins**: Ebenbuild's digital lung twins utilize physics-based simulation and AI to improve treatment outcomes for ICU patients. - **Cellworks Therapy Response Index (TRI)**: An algorithm developed to predict chemotherapy benefits in NSCLC patients, showcasing the potential of biosimulation in personalized medicine. - **AI and ML Integration**: Simulations Plus integrates AI and machine learning with pharmacokinetic modeling to enhance drug discovery. - **DILIsym® version X**: An updated platform from Simulations Plus aimed at improving drug safety predictions in the biopharma industry, particularly for drug-induced liver injury risks. - **GastroPlus X**: A next-generation software launched by Simulations Plus for physiologically based pharmacokinetics and biopharmaceutics modeling, expected to enhance their suite of solutions. - **ADMET Predictor 12**: Simulations Plus released an upgraded version of its platform, enhancing predictive accuracy for drug discovery through advanced machine learning. - **Model-Informed Drug Development (MIDD)**: Utilizes mathematical models to predict drug impact on disease progression and cost-effectiveness, helping mitigate risks in drug development and commercialization. - **Global Biotech Week**: An initiative highlighting the role of biotechnology in healthcare and sustainability, fostering engagement among students and industry leaders. - **Digital Therapeutics**: Software-based interventions for managing diseases, often used alongside clinician guidance. ### Challenges and Concerns - **Regulatory Compliance**: The need for biosimulation tools to ensure compliance with evolving regulatory landscapes, particularly regarding animal testing. - **Data Quality and Calibration**: The accuracy of simulations in biosimulation technologies depends on high-quality calibration data, which can be a limiting factor. - **Regulatory Hurdles**: Navigating regulatory requirements for AI-driven biosimulation and drug development technologies remains a significant concern. - **Cost Barriers**: High costs of biosimulation technologies pose a barrier for smaller companies and academic institutions. - **Clinical Trial Failures**: 90% of drug candidates fail during clinical trials due to issues like lack of efficacy and poor drug properties, which biosimulation aims to address. - **Equitable Implementation**: Addressing gender, economic, and healthcare disparities is crucial for the equitable implementation of biosimulation interventions. - **Data Security**: As biosimulation and AI technologies become more integrated into healthcare, concerns regarding data ownership and cybersecurity are rising. - **Complexity of Biological Modeling**: Building accurate digital twins of human biological systems is challenging due to the complexity of cellular interactions. - **Funding Challenges in Biopharma**: Simulations Plus anticipates challenges due to client-driven data delays affecting project timelines. - **Data Privacy Concerns**: Issues surrounding the security of patient data in the context of IoT and biosensor technologies. - **Data Quality and Availability**: The integration of AI in drug development faces challenges related to the quality and availability of data. - **Regulatory Processes**: The need for streamlined regulatory processes for drug formulations, particularly for long-acting injectables, remains a challenge. - **Data Privacy**: Concerns regarding the security of patient data in remote monitoring systems. - **Ethical Considerations**: The use of AI in healthcare raises ethical questions regarding data privacy and the implications of automated decision-making. - **Underutilization of Remote Patient Monitoring (RPM)**: Despite its benefits, RPM is often underutilized due to geographic and provider availability limitations, highlighting the need for targeted implementation. - **Regulatory Approval Risks**: The failure of drugs to receive regulatory approval in later clinical phases can lead to significant sunk costs for pharmaceutical companies. - **Funding Constraints**: The pharma and biotech sectors have faced constrained funding over the past two years, impacting growth and investment opportunities.